Targeting antibodies for the treatment of aggressive cancer

Targinta develops targeting and toxin-armed antibodies for aggressive cancer. The company was founded based on the discovery of a unique and patent-protected target molecule, integrin α10β1, and the aim is to improve the treatment of cancer, with a focus invasive, hard-to treat cancer forms such as triple-negative breast cancer and the brain cancer glioblastoma.

Read more about Targinta


För närvarande har vi inga event planerade.

Targinta AB, a subsidiary of Xintela AB (publ)

The research that has led to Targinta's oncology venture started in Xintela AB. Targinta is a wholly owned subsidiary of Xintela, which is listed on First North Stockholm.

Copyright © Targinta AB